RESEARCH & DEVELOPMENT AGREEMENT SECOND AMENDMENT Between: Roche Diagnostics GmbH Sandhofer Strasse 16 68305 Mannheim Federal Republic of Germany (hereinafter referred to as “RDG”) and CombiMatrix Corporation
Exhibit
10.18
RESEARCH
& DEVELOPMENT AGREEMENT
SECOND
AMENDMENT
Between:
Roche
Diagnostics GmbH
Sandhofer
Xxxxxxx 00
00000
Xxxxxxxx
Xxxxxxx
Xxxxxxxx of Germany
(hereinafter
referred to as “RDG”)
and
CombiMatrix
Corporation
0000
Xxxxxxx Xxxxxxx Xxxx.
Xxxxxxxx,
XX 00000
XXX
- hereinafter
referred as to “CBMX”
WHEREAS,
the Parties wish to amend their R&D Agreement dated September 25th
2002 as
amended on March 25th
2003 as
follows:
A
New
Article, 4A, shall be inserted in between Section 4.3 and Section 5 as
follows:
“4A.
COMPLETION OF DEVELOPMENT PROGRAM
As
of
December 31st
2003,
RDG’s obligations to make any further payments under Article 4 herein and CBMX’s
obligations to perform further R&D for RDG under Article 2 and Annex I of
the Development Program are terminated. Therefore, as of 03 November 2003,
there
are no further obligations of either party resulting from the R&D Agreement
to make any further payments or to perform any R&D services. As a result,
the Development Program of Annex I of the R&D Agreement shall be terminated
with the effect of December 31st
2003.
IN
WITNESS WHEREOF
the
Parties hereto have signed this Second Amendment:
|
Penzberg,
Germany, March 19, 2004
|
Mukilteo,
Washington March 26, 2004
|
|
Roche
Diagnostics GmbH
|
CombiMatrix
Corporation
|
|
By:
/s/ Xxxxxx Xxxxxxxx
|
By:
/s/ Xxxx Xxxxx
|
|
Xxxxxx
Xxxxxxxx
|
Xxxx
Xxxxx
|
|
i.V.
|
|
|
By:
/s/ Xxxxxx Xxxxxxxxx
|
By:
/s/ Xxxxx Xxxxxxx
|
|
Xxxxxx
Xxxxxxxxx
|
Xxxxx
Xxxxxxx
|
